Synthetic Biologics, Inc. (NYSE:SYN) slipped over -3.32% at $0.6, after hitting low of $0.59 in an intra-day trade. Synthetic Biologics, Inc. has 117.76 million shares outstanding, and in the last trade has seen ATR around 0.04. The volume of SYN witnessed an up move from 1.01 million shares, based on a 50-day average, to 1.27 million shares.
In the most updated research from a number of analysts on Wall Street, the company gets 3 Buys and 0 Sell among 3 analysts. Synthetic Biologics, Inc. (NYSE:SYN) recently traded as high as $0.62. The consensus analyst target price is $5.25. That gives us a street projected return of 775. If the published price targets set by Synthetic Biologics, Inc. analysts have any power to influence the stock’s share price, the highest price target set for SYN is $3.5.
Synthetic Biologics, Inc. most recently reported earnings per share (EPS) of -$0.58 for the 12 months ending 2017-03-31 versus -$0.21 in the same quarter last year, representing 176% growth. Analysts had predicted -$0.07.Revenue during the quarter was $6.56 million, representing -45% growth from $11.9 million in year-ago quarter. The company’s quarterly EPS surprised Wall Street by as much as 729% to the upside in its last earnings announcement, so investors should note this tendency when assessing consensus estimates.
On a similar note, analysts expect EPS of -$0.05 in September 2017 quarter and -$0.06 in December 2017 quarter, representing 44.44% and -175% growth, respectively. They expect this year’s earnings to fall -0.17% year-over-year to $43.1, followed by -60.61% decline in the next year to -$0.27.
Shares of Dunkin’ Brands Group, Inc. (NASDAQ:DNKN) traded down -0.52% in the last session while performance was up 53.22% in the last five days. The stock’s last price was higher from the average trading price of 50 days recorded at $0.57 while enlarging the period to 200 trading days, the average price was $0.7. Currently, 91.67 million total shares are owned by the public and among those 89.77 million shares have been available to trade. The percentage of shares being held by the company management was 0.1% while institutional stake was 86.2%.
Dunkin’ Brands Group, Inc. (DNKN) is recuperating from the fall at $46.55, the 52-week low. The stock has risen 14.33% since then. The trading saw a strength at $59.7, the 52-week high. But since then, those gains have faded by -10.85%. SYN has lost -0.02% in the 1-month period.
Synthetic Biologics, Inc. has a beta of 1.18, offering the possibility of a higher rate of return, but also posing more risk. The portion of a company’s profit allocated to each outstanding share of common stock was $2.29 a share in the trailing twelve months. It last reported revenues of $218.52 million and EPS of $0.6 for the three months that ended 2017-07-01, representing 1% top-line growth and 0.54 EPS growth.
Looking forward, the company’s quarterly earnings are expected to come at $0.63 in the three months through September 2017 and $0.61 in the quarter ending December, reflecting 5% and -4.1% growth, respectively. For the full year, analysts expect earnings to jump 2.43% yoy to $7.35. Next year this growth will reach 8.16% to attain $2.62.